Clinical Trials on Detrusor, Overactive in Ireland

Total 48 results

Mr HD Flood

Unknown

Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity

Overactive Detrusor

Ireland
Women and Infants Hospital of Rhode Island

Unknown

Oral vs Intravesical Analgesia for Office Bladder Botox Injections (OPIL)

Urinary Incontinence | Urge Incontinence | Overactive Bladder Syndrome | Detrusor Instability | Detrusor Hyperreflexia

United States
Astellas Pharma Europe Ltd.

Completed

Vesitirim™ in Men Postmarketing Observational Study (VIM)

Overactive Bladder (OAB) | Lower Urinary Tract Symptoms (LUTS)

Ireland
National University of Ireland, Galway, Ireland
Enterprise Ireland

Completed

Evaluating a Digital Intervention for Overactive Bladder

Overactive Bladder

Ireland
Cork University Hospital

Completed

Analgesic Efficacy of Saphenous Nerve Block in Total Knee Replacement

Post Operative Pain

Ireland
Cork University Hospital

Completed

To Compare lidocaine2%/Clonidine in Combination, With Bupivacaine 0.5 % Alone in Equal Volumes for Combined Sciatic-saphenous Nerve Block in Terms of Selectivity of Blockade

Bimalleolar Fractures of the Ankle. | Sciatic Nerve Block. | Saphenous Nerve Block. | Post Operative Analgesia Duration.

Ireland
Gnankang Sarah Napoe

Recruiting

Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence (BUTTON)

Urinary Incontinence, Urge | Overactive Bladder Syndrome

United States
EvergreenHealth

Completed

Investigating Central Mechanisms of Overactive Bladder in Adults With Parkinson's Disease

Parkinson's Disease

United States
Daniel Burdick, MD
Astellas Pharma US, Inc.

Completed

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO) (Maestro)

Parkinsons Disease

United States
Astellas Pharma Europe Ltd.

Completed

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (BELIEVE)

Urologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urgency Incontinence | Urinary Bladder Overactive

Czechia, Denmark, Greece, Ireland, Slovakia, Spain, Sweden, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Astellas Scientific & Medical Affairs, Inc.

Completed

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) (PERSPECTIVE)

Urologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Canada
University of Limerick

Completed

Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis

Multiple Sclerosis | Urinary Bladder, Overactive | Lower Urinary Tract Symptoms | Urinary Incontinence | Urinary Bladder, Neurogenic | Urinary Incontinence, Urge | Nocturia | Bladder Dysfunction | Neurogenic Bladder Dysfunction | Urinary Frequency More Than Once at Night

Ireland
NICHD Pelvic Floor Disorders Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) (ROSETTA)

Urinary Incontinence, Urge

United States
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Urovant Sciences GmbH

Completed

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

Overactive Bladder With Urge Urinary Incontinence

United States
Watson Pharmaceuticals

Completed

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Overactive Bladder

United States
Duramed Research

Completed

A Safety Extension Study of DR-OXY-301

Overactive Bladder

United States
Pfizer

Completed

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Overactive Bladder

Korea, Republic of, United States, Denmark, Germany, Canada, Hungary, Poland, France, United Kingdom, Slovakia, Sweden, Mexico, Czech Republic, Finland, Italy, Lithuania, Argentina, Chile, Colombia, Egypt, Greece, Norway, Philippines, Russian Federation and more
Pfizer

Completed

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

Overactive Bladder

United States
Velicept Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

Overactive Bladder

United States
Allergan

Completed

BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence (APOLLO)

Urinary Incontinence | Overactive Bladder With Urinary Incontinence

United States, Canada
Pfizer

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Overactive Bladder

Canada, United States, Costa Rica, Hungary, Slovakia, Spain, Colombia, India, Russian Federation, Ireland, Korea, Republic of, Germany, Sweden, Poland, Bulgaria, Estonia, Brazil, Greece, Latvia, Lithuania, Malaysia, Romania, Singapore, South Africa and more
Pfizer

Completed

Fesoterodine Flexible Dose Study

Overactive Bladder

United States
Pfizer

Completed

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Overactive Bladder

United States
GlaxoSmithKline

Completed

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

Overactive Bladder | Incontinence, Urinary and Urinary Bladder, Overactive

United States, Canada
Duramed Research

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder

Overactive Bladder

United States, Canada
Targacept Inc.

Completed

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

Overactive Bladder

United States
Velicept Therapeutics, Inc.

Completed

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) (VEL-2001)

Overactive Bladder

United States
Urovant Sciences GmbH

Completed

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur)

Overactive Bladder

United States, Latvia, Hungary, Canada, Lithuania, Poland
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Post-Operative Pain

United States
University of California, San Francisco
Pfizer

Completed

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES) (BRIDGES)

Overactive Bladder | Urge Urinary Incontinence

United States
Pfizer

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Overactive Bladder

Denmark, United States, Canada, Costa Rica, Belgium, Czech Republic, Colombia, Germany, Hungary, Korea, Republic of, Spain, Chile, Taiwan, India, Brazil, Singapore, Greece, Hong Kong, Italy, Sweden, Poland, South Africa, Malaysia, Rom... and more
Urovant Sciences GmbH

Completed

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). (Empowur)

Overactive Bladder

United States
Sanofi

Completed

MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.

Overactive Bladder

United States
Rigshospitalet, Denmark

Completed

Frequency of Vascular Events With Short-term Thromboprophylaxis in Fast-track Hip and Knee-arthroplasty. (FETA)

Thromboembolic Events | Post-operative Bleeding

Denmark
Duramed Research

Completed

Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder

Urinary Incontinence

United States, Canada
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.

Urinary Bladder, Overactive

United States
Astellas Pharma Inc

Completed

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (SCORPIO)

Urinary Bladder, Overactive

Australia, Belgium, France, Spain, Sweden, Bulgaria, Romania, Italy, Greece, South Africa, Austria, Poland, United Kingdom, Hungary, Denmark, Netherlands, Switzerland, Ireland, Lithuania, Russian Federation, Germany, Latvia, Slovakia, Finlan... and more
Pfizer

Completed

A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

Urinary Bladder, Overactive

Canada, United States, Germany, Russian Federation, Czechia, Egypt, Bulgaria, Finland, Hungary, Korea, Republic of, Mexico, Poland, South Africa, Sweden, Ukraine
Astellas Pharma Inc

Completed

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (TAURUS)

Urinary Bladder, Overactive

Canada, Poland, Belgium, Spain, Sweden, United States, Romania, Italy, France, Austria, United Kingdom, Germany, Hungary, Australia, Denmark, Netherlands, Switzerland, Lithuania, Russian Federation, Latvia, South Africa, Slovakia, F... and more
Astellas Pharma Inc

Completed

Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms (VOLT)

Urinary Bladder, Overactive

United States
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Bausch Health Americas, Inc.

Completed

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

Post Operative Bowel Dysfunction

Germany, Italy, United States, Hungary, Korea, Republic of, South Africa, Poland, Australia, Romania, Former Serbia and Montenegro
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Brown University

Recruiting

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

Arthritis | Chronic Pain | Chronic Low-back Pain | Irritable Bowel Syndrome | Fibromyalgia | Acute Pain | Trauma, Multiple | Neuropathic Pain | Temporomandibular Joint Disorders | Post Operative Pain | Chronic Pain Syndrome | Chronic Shoulder Pain | Painful Diabetic Neuropathy | Chronic Migraine | Painful Bladder Syndrome and other conditions

United States
Medtronic

Recruiting

Product Surveillance Registry (PSR)

Coronary Artery Disease | Renal Insufficiency | Neurological Disorders | Intracranial Aneurysm | Surgical Procedures, Operative | Respiratory Therapy | Minimally Invasive Surgical Procedures | Cardiac Rhythm Disorders | Urological Disorders | Cardiovascular Disorders | Digestive Disorders | Mechanical Circulatory... and other conditions

China, France, Italy, United States, Spain, Australia, Belgium, Denmark, Germany, Greece, Hungary, Israel, Japan, Korea, Republic of, Malaysia, Netherlands, Norway, Portugal, Serbia, Sweden, Switzerland, United Kingdom, Argentina, Brazil and more

Clinical Trials on Detrusor, Overactive in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations